Three independent discounted-cash-flow-style models value Supernus Pharmaceuticals, Inc. every trading day. 0 of 3 currently price SUPN above its market price.
| Free Cash Flow model | $3.32 |
| Excess Profit model | $-25.11 |
| Residual Earnings model | $-1.76 |
| Dividend Discount model | — |
| Piotroski F-Score | 4 / 9 |
| Return on invested capital | -3.5% |
| Net debt / EBITDA | — |
| Gross margin | +89.6% |
| Revenue CAGR | +7.4% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | -2.5% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open SUPN in StockKitty